KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Short-term Investments (2016 - 2025)

Vertex Pharmaceuticals has reported Short-term Investments over the past 17 years, most recently at $1.5 billion for Q4 2025.

  • Quarterly results put Short-term Investments at $1.5 billion for Q4 2025, down 1.49% from a year ago — trailing twelve months through Dec 2025 was $1.5 billion (down 1.49% YoY), and the annual figure for FY2025 was $1.5 billion, down 1.49%.
  • Short-term Investments for Q4 2025 was $1.5 billion at Vertex Pharmaceuticals, up from $1.3 billion in the prior quarter.
  • Over the last five years, Short-term Investments for VRTX hit a ceiling of $1.5 billion in Q4 2024 and a floor of $274.5 million in Q4 2022.
  • Median Short-term Investments over the past 5 years was $931.2 million (2023), compared with a mean of $974.3 million.
  • Biggest five-year swings in Short-term Investments: tumbled 62.39% in 2022 and later surged 209.36% in 2023.
  • Vertex Pharmaceuticals' Short-term Investments stood at $729.9 million in 2021, then tumbled by 62.39% to $274.5 million in 2022, then surged by 209.36% to $849.2 million in 2023, then soared by 82.09% to $1.5 billion in 2024, then fell by 1.49% to $1.5 billion in 2025.
  • The last three reported values for Short-term Investments were $1.5 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.4 billion (Q2 2025) per Business Quant data.